Cargando…

g-Nomic: a new pharmacogenetics interpretation software

We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug–drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabater, Ana, Ciudad, Carlos J, Cendros, Marc, Dobrokhotov, Denis, Sabater-Tobella, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554524/
https://www.ncbi.nlm.nih.gov/pubmed/31239753
http://dx.doi.org/10.2147/PGPM.S203585
_version_ 1783424982177546240
author Sabater, Ana
Ciudad, Carlos J
Cendros, Marc
Dobrokhotov, Denis
Sabater-Tobella, Juan
author_facet Sabater, Ana
Ciudad, Carlos J
Cendros, Marc
Dobrokhotov, Denis
Sabater-Tobella, Juan
author_sort Sabater, Ana
collection PubMed
description We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug–drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabolism pathways. G-Nomic provides a set of recommendations describing the suitability of a given combination of drugs for each patient according to their genes and polymedication. G-Nomic is updated monthly including data from the new drugs to be included, their known interactions, and the relevant pharmacokinetic biomarkers. For the interactions, the list is curated manually, only keeping those with clinical relevance. For each drug, their FDA and EMA drug labels are accessed, to check for relevant enzymes and transport proteins that influence its pharmacokinetics, and for their ability to induce or inhibit other enzymes, particularly the CYP-450 system. When this information is not available, a PubMed search is made to look for these characteristics. In addition, a distinction is made between drugs and prodrugs. A query on the g-Nomic software begins with entering the medication by either their common or commercial name. Non-pharmacological substances can be also added or selected under “lifestyle habits”. The lifestyle list is dynamic, showing only the substances known to interact with the drugs that are currently selected, and includes herb compounds, such as St. John’s wort, as well as proper lifestyle substances such as grapefruit or cigarette smoking. The software provides a list of the genes classified as primary biomarkers as candidates for genetic testing, and a list of the interactions that have been detected. If genetic information is available then, or is made available at a later point, these results can also be entered and the software returns pharmacogenetics recommendations regarding specific genotypes. g-Nomic takes all the above-mentioned parameters in an easy and user-friendly tool making prescription safer.
format Online
Article
Text
id pubmed-6554524
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65545242019-06-25 g-Nomic: a new pharmacogenetics interpretation software Sabater, Ana Ciudad, Carlos J Cendros, Marc Dobrokhotov, Denis Sabater-Tobella, Juan Pharmgenomics Pers Med Methodology We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug–drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabolism pathways. G-Nomic provides a set of recommendations describing the suitability of a given combination of drugs for each patient according to their genes and polymedication. G-Nomic is updated monthly including data from the new drugs to be included, their known interactions, and the relevant pharmacokinetic biomarkers. For the interactions, the list is curated manually, only keeping those with clinical relevance. For each drug, their FDA and EMA drug labels are accessed, to check for relevant enzymes and transport proteins that influence its pharmacokinetics, and for their ability to induce or inhibit other enzymes, particularly the CYP-450 system. When this information is not available, a PubMed search is made to look for these characteristics. In addition, a distinction is made between drugs and prodrugs. A query on the g-Nomic software begins with entering the medication by either their common or commercial name. Non-pharmacological substances can be also added or selected under “lifestyle habits”. The lifestyle list is dynamic, showing only the substances known to interact with the drugs that are currently selected, and includes herb compounds, such as St. John’s wort, as well as proper lifestyle substances such as grapefruit or cigarette smoking. The software provides a list of the genes classified as primary biomarkers as candidates for genetic testing, and a list of the interactions that have been detected. If genetic information is available then, or is made available at a later point, these results can also be entered and the software returns pharmacogenetics recommendations regarding specific genotypes. g-Nomic takes all the above-mentioned parameters in an easy and user-friendly tool making prescription safer. Dove 2019-05-29 /pmc/articles/PMC6554524/ /pubmed/31239753 http://dx.doi.org/10.2147/PGPM.S203585 Text en © 2019 Sabater et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Methodology
Sabater, Ana
Ciudad, Carlos J
Cendros, Marc
Dobrokhotov, Denis
Sabater-Tobella, Juan
g-Nomic: a new pharmacogenetics interpretation software
title g-Nomic: a new pharmacogenetics interpretation software
title_full g-Nomic: a new pharmacogenetics interpretation software
title_fullStr g-Nomic: a new pharmacogenetics interpretation software
title_full_unstemmed g-Nomic: a new pharmacogenetics interpretation software
title_short g-Nomic: a new pharmacogenetics interpretation software
title_sort g-nomic: a new pharmacogenetics interpretation software
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554524/
https://www.ncbi.nlm.nih.gov/pubmed/31239753
http://dx.doi.org/10.2147/PGPM.S203585
work_keys_str_mv AT sabaterana gnomicanewpharmacogeneticsinterpretationsoftware
AT ciudadcarlosj gnomicanewpharmacogeneticsinterpretationsoftware
AT cendrosmarc gnomicanewpharmacogeneticsinterpretationsoftware
AT dobrokhotovdenis gnomicanewpharmacogeneticsinterpretationsoftware
AT sabatertobellajuan gnomicanewpharmacogeneticsinterpretationsoftware